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INTRODUCTION
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The pathological brain changes associated with Alzheimer's disease (AD) occur decades The aforementioned studies were based on community-dwelling cognitively normal 79 individuals, hampering translation to clinical practice. In contrast, persons with subjective 80 cognitive decline (SCD) seek medical help because of self-experienced deterioration in 81 M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT
Timmers -5 cognition, in the absence of objective cognitive deficits, and hence form a clinically relevant 82 study population (Jessen, et al., 2014) . Furthermore, former studies often used dichotomous 83 measures of Aβ or crude cognitive tests, possibly lacking sensitivity to detect subtle changes 84 related to the first changes in AD. 85 In this study, we investigated individuals with SCD from a memory clinic cohort who 86 underwent dynamic amyloid-β PET scanning to accurately quantify Aβ load and an extensive 87 repeated neuropsychological test battery. We investigated the relationships between specific 88 amyloid-β PET binding and 1) concurrent and 2) longitudinal cognitive performance in SCD. 
MATERIAL & METHODS
91
Participants
92
We included 107 participants with SCD from the ongoing Subjective Cognitive Impairment Medical Center Alzheimer Center (Slot, et al., 2018) . All participants underwent extensive 95 diagnostic work-up including neurological examination, neuropsychological assessment, 96 laboratory tests and brain magnetic resonance imaging (MRI) (van der Flier and Scheltens, 97 2018). In a consensus meeting, a diagnosis of SCD was made when cognitive functioning was 98 within normal limits, and criteria for mild cognitive impairment (MCI), dementia, or any 99 other neurological or psychiatric disorder likely to cause cognitive symptoms, were not met. 100 Subsequently, participants with a diagnosis of SCD were invited to participate in SCIENCe, a 101 prospective cohort study with annual neurological examinations and neuropsychological 102 assessment. Education was evaluated using the Dutch Verhage system (ranging from 1 [low] 103 to 7 [high]) (Verhage and Van Der Werff, 1964) . At each follow-up visit, diagnosis was re-104 evaluated, and when progression to MCI or dementia was detected, participants were referred 105 
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Five participants (4.7 %) showed clinical progression to MCI during follow-up.
231
Supplementary cognitive domain scores (Table 3) . showed that associations between Aβ and cognition were largely consistent when using an 301 M A N U S C R I P T A., Baracchi, F., Girouard, H., Misoch, S., Giacobini, E., Depypere, H., Hampel, H., Women's 478 M A N U S C R I P T Jansen, W.J., Ossenkoppele, R., Knol, D.L., Tijms, B.M., Scheltens, P., Verhey, F.R., Visser, P.J., 514
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HIGHLIGHTS
• We performed quantitative amyloid-β PET in subjects with subjective cognitive decline (SCD).
• Cognitively normal SCD subjects with higher amyloid-β had poorer concurrent MMSE.
• Higher amyloid-β was associated with steeper decline in several cognitive domains.
• Associations between amyloid-β and cognition were most pronounced in the memory domain
